Tarsus Pharmaceuticals Chief Medical Officer Lin Elizabeth Yeu sold 13,953 shares at prices ranging from $85 to $90 per share on 2026-09-04. Investors can see the reported transaction type, the sale date and Yeu’s remaining 1,590-share position after the transactions.
Key Highlights
- Yeu’s sale prices ranged from $85 to $90 per share.
- Yeu retained 1,590 shares after the transactions.
- All reported entries used transaction code S, denoting open-market sales.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) Chief Medical Officer Lin Elizabeth Yeu sold 13,953 shares on 4 September 2026 across multiple transactions. The reported activity left Yeu holding 1,590 shares of Tarsus Pharmaceuticals, Inc.
$85-$90 Per-Share Sale Range
The transactions were completed at prices ranging from $85 to $90 per share. Yeu was identified as Tarsus Pharmaceuticals’ Chief Medical Officer. The per-share price range applies to the shares sold in the reported activity.
Post-Sale Ownership
Yeu’s reported ownership after the transactions stood at 1,590 shares. That balance represents her remaining position following the sales described in the transaction records. The records connect the sale activity with Yeu’s post-transaction ownership.
FAQs
Q: How many Tarsus Pharmaceuticals shares did Lin Elizabeth Yeu sell?
A: Tarsus Pharmaceuticals Chief Medical Officer Lin Elizabeth Yeu sold 13,953 shares. The transactions occurred on 4 September 2026 at prices ranging from $85 to $90 per share.
Q: What was the impact of the Tarsus Pharmaceuticals insider sale?
A: The reported insider sale involved Tarsus Pharmaceuticals Chief Medical Officer Lin Elizabeth Yeu selling 13,953 shares on 4 September 2026. Following the transactions, she held 1,590 shares.
Q: What price did the Tarsus Pharmaceuticals CMO receive?
A: Lin Elizabeth Yeu’s Tarsus Pharmaceuticals shares were sold at prices ranging from $85 to $90 per share. The transactions were recorded on 4 September 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.